Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II ‐Induced Cardiac Hypertrophy
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Ke Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hangzhou Medical College, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Angiotensin II, Cardiomegaly, Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research Project of Wenzhou City, Innovation Team of Hangzhou City.
Abstract (Originalsprache)
Hypertension is the leading cause of cardiac remodelling and heart failure. Recent evidence has highlighted the role of the non‐hemodynamic function of angiotensin II in hypertension. MyD88 is the canonical adaptor of TLRs and IL‐1Rs, which serves as the central node in regulating inflammatory responses. Previous studies reported the opposite roles of MyD88 in hypertension. In this study, we aimed to determine the role of MyD88 and the underlying mechanisms in hypertension. Cardiomyocyte‐specific MyD88 knockout mice, macrophage‐specific MyD88 knockout mice, and MyD88 inhibitor‐treated mice were challenged with Ang II infusion to establish a cardiac remodelling model. An inflammatory cytokine array was used to determine the internal mediators. Our results showed that cardiomyocyte MyD88 deficiency showed little protection, whereas macrophage MyD88 deficiency and pharmacological MyD88 inhibition using LM8 significantly ameliorated Ang II‐induced cardiac inflammation, fibrosis, and dysfunction. The cytokine and chemokine array demonstrated that CXCL1 and CCL2 were differentially expressed between cardiomyocyte‐specific MyD88 knockout and macrophage‐specific MyD88 knockout mice. Deletion of MyD88 in macrophages significantly decreased macrophage infiltration and suppressed the activation of macrophages, which then reduced the conditioned medium‐induced cardiomyocyte hypertrophy. Our study demonstrated that targeting myeloid MyD88 could be a potential strategy in treating hypertensive cardiac remodelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hangzhou Medical College, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou, Zhejiang, China.
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
- School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang, China.
ORCID-Profile: Wu Luo, Guang Liang, Yi Wang
Förderung
- Key Research Project of Wenzhou City
- Innovation Team of Hangzhou City
Zitieren
APA
Lin, K., Yang, N., Hu, C., Luo, W., Huang, P., Liang, G., & Wang, Y. (2025). Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II ‐Induced Cardiac Hypertrophy. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70733
Vancouver
Lin K, Yang N, Hu C, Luo W, Huang P, Liang G, et al. Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II ‐Induced Cardiac Hypertrophy. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70733
BibTeX
@article{Lin2025,
author = {Lin, Ke and Yang, Na and Hu, Chenghong and Luo, Wu and Huang, Ping and Liang, Guang and Wang, Yi},
title = {Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II ‐Induced Cardiac Hypertrophy},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70733}
}
EUVIMED